Efficacy And Outcomes Of Presbyopia - Correcting Intraocular Lens Implantation In Patients With Glaucoma And Glaucoma Suspect

This study aims to evaluate the visual and functional outcomes of presbyopia-correction intraocular lens (IOL) implantation in patients diagnosed with glaucoma or ocular hypertension undergoing cataract surgery.

Single-center retrospective study conducted at Kim's eye hospital

A retrospective analysis was conducted on patients who received extended depth of focus (EDOF)  or multifocal IOL implantation between January 2019 and April 2022. A total of 38 eyes from 28 patients were included in the study. The mean age of the patients was 62.6 ± 7.73 years, with 11 males and 17 females. The implanted IOLs included Symfony, Eyhance, PanOptix, and Vivity. Preoperative and postoperative visual acuity (VA) and visual field (VF) parameters were compared.

Among the implanted lenses, Symfony was used in 23 eyes, Eyhance in 8 eyes, PanOptix in 4 eyes, and Vivity in 2 eyes. The mean preoperative visual acuity was logMAR 0.21 (Snellen 0.6), and the mean visual field indices were MD -5.31 ± 3.36 dB and VFI 89.57 ± 7.78%. Postoperatively, the mean visual acuity improved significantly to logMAR 0.005 (Snellen 1.0), while the visual field indices (MD -4.68 ± 2.73 dB, VFI 89.59 ± 7.19%) remained stable without significant deterioration. These results indicate that while multifocal IOLs improved visual acuity, they did not negatively impact the visual field.

Although multifocal IOLs may lead to a reduction in contrast sensitivity, which is a crucial concern in glaucoma patients, our findings suggest that these lenses can still provide favorable visual outcomes. While multifocal IOL implantation is not yet widely adopted in glaucoma patients due to concerns about contrast sensitivity, the results of this study indicate that careful patient selection may allow for successful outcomes even in this population.